Clinical Trial Update: First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A first-in-human Phase 1/2 study of AZD8359 STEAP2 TCE is planned for metastatic prostate cancer and is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AZD8359 STEAP2 TCE (STEAP2-targeted T cell engager)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Prostate Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING